EX-99.3 4 factsheet.htm EX. 99.3 FACT SHEET- WORD
PAGE 1
Investor Fact Sheet
Ticker Symbol: NASDAQ: CEMI
www.chembio.com

Business Summary & Investment Highlights
Chembio Diagnostics, Inc., (Chembio), through its wholly-owned subsidiary Chembio Diagnostic Systems, Inc. develops, manufactures, licenses and markets point-of-care testing (POCT) products.  Chembio created and patented a new revolutionary technology called Dual Path Platform (DPP®). The technology is addressing critical market requirements in the infectious diseases testing market and other growing markets. Products under development, both OEM and branded, are anticipated to create significant new revenue streams that will add to Chembio's core business of rapid HIV tests.
·
Ten Consecutive Years of Double Digit Revenue Growth and Five Consecutive Years of Profitability.
·
Strategy is to create core business of public health products to be complemented by OEM and selected out-licensing opportunities.
·
Robust pipeline of POCT products for infectious diseases based on Chembio's patented DPP® technology.
·
Products developed on DPP® platform include oral fluid HIV test approved by FDA in December 2012.   Several other products and collaborations in pipeline.
·
Commercial Activities in North America, South America, Europe, Africa and Asia Ongoing to Address Growing Global Market for POCTs
Selected Financial Information
Stock Information  as of 7/31/14
Ticker Symbol: NASDAQ: CEMI
Price 07/31/2014:   $3.33
52 Week High:     $5.00
52 Week Low:   $2.83
Outstanding Shares (MM): 9.61
Market Capitalization (MM): $32.10
Fully Diluted (FD) Shares (MM): 10.28
Management Holding-FD (MM):0.97
Average Daily Vol. (3 Mos):  20,000

5% Beneficial Holders Beneficial Shares Owned (000)s
Wellington Management Company, LLP: 958 
Lawrence Siebert: 840
 
See Graphics
 
 
 
 
 
  
   
 
Balance Sheet Data ($000s)
  
June '14
    
Dec '13
  
Cash
  
$
6,835
    
$
9,650
  
Accts. Receivable
    
5,423
      
4,592
  
Inventories
    
4,079
      
3,189
  
Total Current Assets
    
17,481
      
17,431
  
Net Fixed Assets
    
2,127
      
1,978
  
Total Assets
    
24,057
      
19,409
  
Total Current Liab.
    
3,796
      
4,309
  
Total Other Liab.
    
-
      
-
  
Total Liabilities
    
3,796
      
4,309
  
Shareholders Equity
    
20,261
      
20,177
  
Total Liabilities & Shareholders Equity
  
$
24,057
    
$
24,486
  
 
 
 
 
 
 
Selected Comparative Historical Financial Data
 
 
    
   
   
   
   
   
 
Quarter/Year Ended
    
For the Quarter Ended
    
For the Six Months Ended
    
For the Years Ended  
 
$
(000s
)
  
Q2'14
    
Q2'13
    
Q2'14
    
Q2'13
      
2013
      
2012
      
2011
      
2010
  
Total Revenues
    
$
7,423
    
$
5,394
      
13,236
      
12,072
    
$
29,550
    
$
25,611
    
$
19,388
    
$
16,705
  
Cost of sales
      
4,440
      
3,112
      
7,981
      
7,097
      
17,249
      
14,821
      
9,998
      
8,604
  
Gross Profit
      
2,983
      
2,282
      
5,255
      
4,975
      
12,301
      
10,790
      
9,390
      
8,101
  
         
40.2
%
    
42.3
%
    
39.7
%
    
41.2
%
    
41.6
%
    
42.1
%
    
48.4
%
    
48.5
%
R&D Expense
      
1,269
      
1,501
      
2,466
      
2,546
      
5,834
      
4,486
      
4,878
      
2,586
  
SG&A Expense
      
1,947
      
1,160
      
3,404
      
2,322
      
5,461
      
4,852
      
3,424
      
2,941
  
Operating Income (Loss)
      
(233
)
    
(379
)
    
(615
)
    
107
      
1,006
      
1,452
      
1,088
      
2,574
  
Other Inc. (Expense)
      
(4
)
    
8
      
(2
)
    
9
      
13
      
(1
)
    
(12
)
    
(15
)
Net Income (Loss)
      
(237
)
    
(371
)
    
(617
)
    
116
      
1,019
      
1,451
      
1,076
      
2,559
  
Inc Tax (Ben.) Prov.
      
(91
)
    
(130
)
    
(247
)
    
40
      
487
      
509
      
(5,133
)
    
-
  
Net Income (Loss)
    
$
(146
)
  
$
(241
)
    
(370
)
    
76
    
$
532
    
$
942
    
$
6,209
    
$
2,559
  
Net Income (Loss) - per Share
      
(0.02
)
    
(0.03
)
    
(0.04
)
    
0.01
    
$
0.06
    
$
0.11
    
$
0.73
    
$
0.29
  
Wt. Avg. No. Shares (Millions)
      
9.556
      
9.260
      
9.448
      
8.664
      
9.520
      
8.615
      
8.556
      
8.865
  
Working capital
    
$
13,686
    
$
13,189
      
13,686
      
13,189
      
14,221
      
7,630
      
6,134
      
4,560
  
Total assets
      
24,057
      
23,542
      
24,057
      
23,542
      
24,487
      
17,335
      
15,486
      
9,086
  
Total liabilities
      
3,796
      
3,929
      
3,796
      
3,929
      
4,310
      
3,460
      
2,991
      
3,277
  
Shareholders Equity
      
20,261
      
19,613
      
20,261
      
19,613
      
20,177
      
13,875
      
12,495
      
5,809
  
 
 
 
 Chembio Diagnostics, Inc.
Investor Relations
 Company Contact
 3661 Horseblock Road
Vida Strategic Partners
Susan Norcott
 Medford, NY 11763
Stephanie C. Diaz
 631-924-1135 x125
 Ph. 631-924-1135
(415) 675-7401
 snorcott@chembio.com
 Fax 631-924-2065
sdiaz@vidasp.com
 
 www.chembio.com
 
 


PAGE 2 – See Graphics

DPP® Technology
Competitive Advantages For POC Testing

• Improved Sensitivity - enabled by more efficient binding method
• Easier Multiplexing - due to even and direct distribution of sample to multiple test lines
• Enhanced Sample Control - as result of independent sample migration path
• Clearer Results - efficient binding allows for improved functionality of instruments for reading and reporting of qualitative or quantitative results


Senior Management Team
John J. Sperzel, President & CEO: 25+ years of leadership in the POC Diagnostics market
Richard J. Larkin, CFO: 25+ years of leadership in Finance and Administration
Sharon Klugewicz, COO: 20+ years of leadership in Operations, Marketing, QA/RA
Javan Esfandiari, CSTO: 15+ years developing POC IVD tests and inventor of DPP®  technology
Michael Steele, VP Sales/Marketing/BD: 20+ years of commercial operations and BD IVD market
Tom Ippolito, VP RA: 20+ years of Quality and Regulatory Affairs leadership in IVD and Pharma

Independent Directors
Katherine Davis (Chairman) - Former Lieutenant Governor for the State of Indiana
Barbara DeBuono, MD, MPH: former NY Commissioner of Health and RI Director of Health
Peter Kissinger, Ph.D.: founder of a number of biotechnology / biomedical companies
Gary Meller, MD, MBA: broad experience in medical and information technology


Except for the historical information contained herein, the matters discussed in this document are forward-looking statements, the accuracy of which is subject to risks and uncertainties. Please refer to Chembio Diagnostic's Inc. most recent Form 10-K and Forms 10-Q for additional information about the Company and related risks. –August 2014